NUVB — Nuvation Bio Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1811063 ·
Last close
$3.90
Market Cap
$1.37B
52W High
$9.75
52W Low
$3.79
ADV30
5,229,568
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 44,951,000 33,022,000 -42,210,000 -41,899,000 778,392,000 153,766,000 550,417,000
Jun 2026 31,687,000 22,216,000 -51,036,000 -62,840,000 744,503,000 258,604,000 490,639,000
Mar 2026 83,228,000 77,237,000 3,881,000 5,397,000 610,241,000 125,391,000 290,677,000
Dec 2025 41,865,000 40,586,000 -34,037,000 -36,592,000 594,822,000 164,086,000 289,106,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-106,194,000
Investing CF
$-59,906,000
Financing CF
$221,801,000
CapEx
$-1,979,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.40
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,214,712,000
Inventory
$15,337,000
Receivables
$40,221,000
ST Investments
$509,604,000
EBIT TTM
$-109,678,000
Pretax Income TTM
$-135,934,000
Interest Exp TTM
$26,256,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$201,731,008
EBITDA
$-121,213,000
Free Cash Flow
$-76,062,248
Enterprise Value
$1,273,308,416
Total Cash
$663,369,984
Total Debt
$468,124,992
Shares Out
352,017,638
Trailing EPS
$-0.39
Book Value
$0.65
ROE
-49.1%
ROA
-11.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 62,902,000 -213,064,000 -204,627,000 594,822,000 289,106,000 305,716,000 -173,427,000
Dec 2024 7,873,000 -167,557,000 -567,939,000 540,626,000 76,838,000 463,788,000 -130,413,000
Dec 2023 0 -99,822,000 -75,802,000 621,484,000 16,362,000 605,122,000 -67,999,000
Dec 2022 0 -119,734,000 -104,199,000 672,141,000 17,065,000 655,076,000 -96,108,000

TTM Snapshot

Revenues TTM
$169,900,000
NetIncome TTM
$-149,827,000
OpCashFlow TTM
—
Assets (Latest)
$744,503,000
Forward EPS
$-0.01

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $3.78 · call volume: 57 · put volume: 544
Expected Move to 2026-12-18: ±$1.29 (34.13%) — implied range $2.49 – $5.07 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ANAB ANAPTYSBIO, INC $1.36B $45.61 —
TYRA Tyra Biosciences, Inc. $1.35B $19.57 —
NBTX Nanobiotix S.A. $1.39B $27.45 —
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —

News headlines (Yahoo Finance, 1h cache)

Nuvation Bio (NUVB) On Safusidenib Data And Why The Undervaluation Narrative Persists
2026-11-19 01:15 · Yahoo
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
2026-11-16 13:00 · Yahoo
Nuvation Bio And 2 More Penny Stocks To Watch
2026-11-11 09:13 · Yahoo
Nuvation Bio (NUVB) Stock Trades Below Fair Value After Its 211% Run
2026-11-10 23:21 · Yahoo
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
2026-11-10 21:05 · Yahoo
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
2026-11-08 16:14 · Yahoo
Nuvation Bio (NUVB) Q3 2026 Earnings Call Transcript
2026-11-05 15:13 · Yahoo
Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as ...
2026-11-05 09:12 · Yahoo
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 21:50 · Yahoo
Top 3 Penny Stocks To Watch In November 2026
2026-11-03 14:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.